SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Rafarma Pharmaceuticals, Inc. (RAFA) trades at a trailing P/E of 21.7. Trailing earnings yield is 4.61%.
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (21.7); earnings yield beats bond yields (4.61%).
- Trailing Earnings Yield 4.61% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
Overall SharesGrow Score: 49/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RAFA
Valuation Multiples
P/E (TTM)21.7
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.63
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.10
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.61%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2014 |
$0.00 |
$0.00 |
$-14.85K |
- |
| 2017 |
$0.00 |
$125.1K |
$-97.07K |
-77.6% |
| 2018 |
$0.00 |
$147.2K |
$-6.18K |
-4.2% |
| 2019 |
$0.03 |
$11.44M |
$3.05M |
26.7% |
| 2020 |
$0.17 |
$74.73M |
$14.85M |
19.9% |
| 2021 |
$0.13 |
$77.41M |
$11.57M |
15% |
| 2022 |
$0.06 |
$64.31M |
$4.96M |
7.7% |
| 2023 |
$0.00 |
$10.14M |
$273K |
2.7% |
| 2024 |
$0.00 |
$9.08M |
$266K |
2.9% |
